Subscribe

Sipai Health Technology Co., Ltd. (0314.HK)

HKD1.39 +0.01 (+0.72%)
CN HKSE Healthcare Medical - Healthcare Plans
Address 7/F, Building 3, Xingguangyao Plaza, No. 1888 Caoyang Road, Putuo District 200063
Shanghai, CN
CEO Xuguang Ma
Website medbankshealthtech.com
IPO 2022-12-23
ISIN KYG8192S1021

Explore sections of this company profile

Description

Sipai Health Technology Co., Ltd. is a Chinese enterprise specializing in medical technology and health management. Its business operations are diversified across three primary divisions: Specialty Pharmacy, Physician Research Assistance, and Health Insurance Services. The Specialty Pharmacy division manages a network of dedicated pharmacies and is also involved in the distribution of pharmaceutical products to drug manufacturers and other supply chain partners. Through its Physician Research Assistance segment, Sipai Health provides comprehensive site management organization (SMO) support to pharmaceutical firms and clinical research institutions. These services encompass a broad spectrum, including site identification and setup, patient acquisition and oversight, data and document handling, on-site logistical management of drugs and biosamples, and trial conclusion. Additionally, this segment offers specialized image management for clinical studies. The Health Insurance Services division functions as an intermediary, delivering brokerage solutions to various insurance providers. Established in 2014, the company's headquarters are situated in Guangzhou, China.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
HKD1.39 +0.01 (+0.72%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
966.0K
Beta
-0.60
Float Shares
354.65M
Free Float %
48.3%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.00% +5.07% +7.41% -40.57% -35.84% -41.77% -62.44% -95.51% -94.20% -94.20% -94.20%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
1.39
Ratings Trend (MoM) 100% Bullish
Rating 2025-10 Change
Strong Buy 0 0
Buy 1 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
-4.05
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Medical - Healthcare Plans: +11.8%
    -55.8% Q2'25: -48.2% (vs Q2'24)
  • ✗
    EPS growth Medical - Healthcare Plans: -1.4%
    +60.8% ★ Q2'25: +3.3% (vs Q2'24)
  • ✗
    FCF margin FCF growth · Medical - Healthcare Plans: +15.1%
    -1.4% Q2'25: +0.0% (vs Q2'24)
  • ✗
    EBIT margin Medical - Healthcare Plans: +3.3%
    -5.0% Q2'25: -4.9% (vs Q2'24)
  • ✗
    ROIC Medical - Healthcare Plans: +6.7%
    -39.5% Q2'25: -39.7% (vs Q2'24)
  • ✓
    Share dilution Medical - Healthcare Plans: +2.1%
    -5.8% ★ Q2'25: -4.9% (vs Q2'24)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Medical - Healthcare Plans: 0.93×
    -0.30× Q2'25: -0.21× (vs Q2'24)
Valuation Multiples From To
DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (-0.62) × ERP
WACC = 97% × Ke + 3% × Kd (6.2%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 1.39
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana.
Revenue
4.71B
est: 5.17B (-8.9%)
4.57B
est: 5.47B (-16.5%)
2.02B
est: 2.05B (-1.8%)
1.99B
1.99B – 1.99B
-2.9% YoY
2.08B
2.08B – 2.08B
+4.1% YoY
EBITDA
-226.10M
est: -1.05B (+78.5%)
-259.52M
est: -742.24M (+65.0%)
-75.52M
est: -278.99M (+72.9%)
-270.82M
-270.82M – -270.82M
+2.9% YoY
-282.04M
-282.04M – -282.04M
-4.1% YoY
EBIT
-242.18M
est: -1.08B (+77.5%)
-274.35M
est: -774.04M (+64.6%)
-101.71M
est: -290.94M (+65.0%)
-282.43M
-282.43M – -282.43M
+2.9% YoY
-294.12M
-294.12M – -294.12M
-4.1% YoY
Net Income
-255.77M
est: -127.33M (-100.9%)
-323.74M
est: -60.18M (-437.9%)
-121.05M
est: -78.24M (-54.7%)
-24.98M
-24.98M – -24.98M
+68.1% YoY
18.73M
18.73M – 18.73M
+175.0% YoY
SGA
640.11M
est: 847.86M (-24.5%)
602.32M
est: 1.03B (-41.5%)
358.34M
est: 387.30M (-7.5%)
375.97M
375.97M – 375.97M
-2.9% YoY
391.53M
391.53M – 391.53M
+4.1% YoY
EPS
-0.40
est: -0.20 (-100.8%)
-0.51
est: -0.10 (-410.2%)
-0.20
est: -0.13 (-53.9%)
-0.04
-0.04 – -0.04
+68.1% YoY
0.03
0.03 – 0.03
+175.0% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-28 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-27 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-26 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-22 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-21 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-20 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-19 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-18 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-15 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-14 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-13 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-12 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-11 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-08 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-07 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-06 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-05 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-04 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-04-30 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-04-29 C 2/5 1/5 1/5 1/5 3/5 1/5 3/5
2026-04-28 C 2/5 1/5 1/5 1/5 3/5 1/5 3/5
2026-04-27 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-04-24 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-04-23 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-04-22 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-04-21 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-04-20 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-04-17 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-04-16 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-84.79M
OE per share TTM
-0.14
Owner's Yield
-9.78%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
2.5%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 3 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 State Street SPDR S&P Emerging Markets Small Cap ETF EWX 0.01% 45.9K 0.65%
2 Dimensional - Emerging Markets Core Equity 2 ETF DFEM 0.00% 35.6K 0.39%
3 State Street SPDR S&P China ETF GXC 0.00% 1.7K 0.59%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-31.4K
Shares Outstanding
734.00M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Xuguang Ma Chief Executive Officer & Executive Chairman 2M male
Ji Li President & Executive Director 2M male
Ching Yi Li Joint Company Secretary — female
Na Ren General Counsel & Company Secretary — female
Qi'ang Li Chief Operating Officer — male
Teng Zhou Chief Strategy Officer — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Healthcare Plans